Document:

ex10-1.htm

 

Exhibit 10.1

 

AMENDMENT NO. 2 TO

STOCK PURCHASE AGREEMENT

This AMENDMENT NO. 2 TO STOCK PURCHASE AGREEMENT (this “Amendment”) is made as of the 25th day of March, 2016, by and between Arotech Corporation, a Delaware corporation (the “Company”) and Admiralty Partners, Inc., a Delaware corporation (the “Investor”).

WHEREAS, the parties hereto have entered into that certain Stock Purchase Agreement dated as of February 3, 2016, as amended on February 23, 2016 (the “Purchase Agreement”); and

WHEREAS, the Parties desire to further amend the Purchase Agreement as set forth herein.

NOW, THEREFORE, in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1.           Definitions.  Any capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement.

2.           Voting Agreement Term.  The definition of “Voting Agreement Term,” defined in Section 8.1 of the Purchase Agreement as being until July31, 2018, is hereby changed to being until July 31, 2017, such that the first clause at the beginning of Section 8.1 reads as follows:

“The Investor hereby agrees that, until July 31, 2017 (the “Voting Agreement Term”),...”

3.           No Other Amendments, Modifications or Waivers.  Except as expressly set forth herein, (a) nothing contained herein shall be deemed to constitute an amendment, modification or waiver, express or implied, of any term or provision of the Purchase Agreement or any other Transaction Document and (b) the Purchase Agreement and all other Transaction Documents are and shall remain in full force and effect in accordance with their terms.

4.           Miscellaneous.  The provisions of Section 10 (Miscellaneous) of the Purchase Agreement shall apply mutatis mutandis to this Amendment.

5.           Counterparts; Electronic Signature.  This Amendment may be executed in multiple counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement. This Amendment may be executed by facsimile or electronic (.pdf) signature and a facsimile or electronic (.pdf) signature shall constitute an original for all purposes.

[Remainder of Page Intentionally Left Blank]

 

  

  

  

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

 

	
The Company:

	
AROTECH CORPORATION

	  	  
	 	
By: /s/ Steven Esses                               

	 	
Name: Steven Esses

	 	
Title: President and CEO

	  	  
	 	 
	
The Investor:

	
ADMIRALTY PARTNERS, INC.

	  	  
	 	
By: /s/ Jon B. Kutler                                

	 	
Name: Jon B. Kutler

	 	
Title: Chairman and CEO

 

 

 

 

  

[Signature Page to Amendment No. 2 to Stock Purchase Agreement]EX-10.1

 EXHIBIT 10.1 

AMENDMENT NO. 1 TO 

AMENDED AND RESTATED PATENT AND TECHNOLOGY 

LICENSE AGREEMENT 
 This
Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (the “Amendment No. 1”), effective as of October 22, 2015 (the “Amendment No. 1 Effective Date”), is entered into by and between Fred
Hutchinson Cancer Research center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (“FHCRC”), and Juno Therapeutics, Inc., a Delaware corporation having offices
located at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98019 (“LICENSEE”). 
 WHEREAS, the parties entered
into an Amended and Restated Patent and Technology License Agreement dated as of January 2, 2012 (the “Original Agreement”); and 

WHEREAS, the parties wish to amend the Original Agreement under the terms and conditions herein. 

NOW THEREFORE, in consideration of the premises and mutual promises set forth in this Agreement, and other good and valuable consideration,
the exchange, receipt and sufficiency of which are acknowledged, FHCRC and LICENSEE hereby agree as follows: 
 1. Definitions. The
term “Agreement” as used in this Amendment No. 1 and in the Original Agreement shall mean the Original Agreement as amended hereby. Except as otherwise set forth herein, the capitalized terms used herein and in the Original
Agreement shall have the meaning set forth in the Original Agreement. 
 2. Survival of Agreement Terms. Except as expressly set
forth herein, the terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Amendment No. 1 and the Original Agreement, the terms and conditions
set forth in this Amendment No. 1 shall control with respect to the subject matter hereof. 
 3. Amendment. The amendments made
hereby are made pursuant to Section 14.1 of the Original Agreement. 
 4. Consideration. 

 

	 	a.	As additional consideration for adding provisional application United States serial number [***] entitled “[***]” and filed on [***] to Exhibit A, Juno will pay [***] within [***] after execution of this
Amendment No. 1. 

  

	 	b.	As additional consideration for adding provisional application United States serial number [***] entitled “[***]” and filed on [***] to Exhibit A, Juno will pay a [***] within [***] after execution of this
Amendment No. 1. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 1 of 5	 	Juno Confidential

 5. Exhibit A. Exhibit A of the Original Agreement is hereby deleted and replaced in
its entirety with the Exhibit A attached hereto. 
 6. Miscellaneous. This Amendment No. 1 may be executed in two (2) or more
counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument, with facsimile and .pdf signatures binding as if originally executed. No agreements altering or supplementing the terms
hereof will be made except by a written document signed by both parties. This Amendment No. 1 will be governed by, construed and enforced in accordance with the internal laws of the State of Washington, without giving effect to principles and
provisions thereof relating to conflict or choice of laws irrespective of the fact that any one of the parties is now or may become a resident of a different state. 

IN WITNESS WHEREOF, the Parties have caused this Amendment No. 1 to be signed by their duly authorized representatives as of the Amendment No. 1 Effective
Date. 
  

					
	FRED HUTCHINSON CANCER	 		 	JUNO THERAPEUTICS, INC.
	RESEARCH CENTER	 		 	
			
	 /s/ Nicole C. Robinson
	 		 	 /s/ Hans Bishop

	Signature	 		 	Signature
			
	 Nicole C. Robinson, Ph.D.
	 		 	 HANS BISHOP

	Printed Name	 		 	Printed Name
			
	 Vice President, Business Development & Industry Relations
	 		 	 CHIEF EXECUTIVE OFFICER

	Title	 		 	Title
			
	 10/22/15
	 		 	 OCTOBER 22, 2015

	Date	 		 	Date

 [Signature Page to Amendment No. 1 to Amended and Restated Patent and 

Technology License Agreement] 

  

					
		 	Page 2 of 5	 	Juno Confidential

 EXHIBIT A 

LICENSED SUBJECT MATTER 

(as of October 6, 2015) 
  

					
	SeedIP Ref (360056-)	  	 Application No.
  

Patent No./
 Publication
No.
	  	 Filing Date
  

Publication/ Issue

Date
  

(MM-DD-YYYY)

 420 Family 

[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 3 of 5	 	Juno Confidential

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 4 of 5	 	Juno Confidential

 430 Family 

[***] 
 431 Family 

[***] 
 All U.S. and ex-U.S. patents and patent
applications, including all continuations, divisionals, patents of addition, reissues, renewals, extensions and all foreign counterparts and continuations in part to the extent that such continuations in part contain subject matter related to any of
the U.S. and ex-U.S. patents and patent applications identified above in this Exhibit A. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 5 of 5	 	Juno ConfidentialEX-10.2(A)

 EXHIBIT 10.2(A) 

AMENDMENT NO. 1 TO 

AMENDED AND RESTATED PATENT AND TECHNOLOGY 

LICENSE AGREEMENT 
 This
Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (the “Amendment No. 1”), effective as of October 22, 2015 (the “Amendment No. 1 Effective Date”), is entered into by and between Fred
Hutchinson Cancer Research center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (“FHCRC”), and Juno Therapeutics, Inc., a Delaware corporation having offices
located at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98019 (“LICENSEE”). 
 WHEREAS, the parties entered
into an Amended and Restated Patent and Technology License Agreement dated as of October 16, 2013 (the “Original Agreement”); and 

WHEREAS, the parties wish to amend the Original Agreement under the terms and conditions herein. 

NOW THEREFORE, in consideration of the premises and mutual promises set forth in this Agreement, and other good and valuable consideration,
the exchange, receipt and sufficiency of which are acknowledged, FHCRC and LICENSEE hereby agree as follows: 
 1. Definitions. The
term “Agreement” as used in this Amendment No. 1 and in the Original Agreement shall mean the Original Agreement as amended hereby. Except as otherwise set forth herein, the capitalized terms used herein and in the Original
Agreement shall have the meaning set forth in the Original Agreement. 
 2. Survival of Agreement Terms. Except as expressly set
forth herein, the terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Amendment No. 1 and the Original Agreement, the terms and conditions
set forth in this Amendment No. 1 shall control with respect to the subject matter hereof. 
 3. Amendment. The amendments made
hereby are made pursuant to Section 15.1 of the Original Agreement. 
 4. Consideration. As additional consideration for adding
provisional application United States serial number [***] entitled “[***]” and filed on [***] to Exhibit A, Juno will pay [***]. 

5. Exhibit A. Exhibit A of the Original Agreement is hereby deleted and replaced in its entirety with the Exhibit A attached
hereto. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 1 of 7	 	Juno Confidential

 6. Miscellaneous. This Amendment No. 1 may be executed in two (2) or more
counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument, with facsimile and .pdf signatures binding as if originally executed. No agreements altering or supplementing the terms
hereof will be made except by a written document signed by both parties. This Amendment No. 1 will be governed by, construed and enforced in accordance with the internal laws of the State of Washington, without giving effect to principles and
provisions thereof relating to conflict or choice of laws irrespective of the fact that any one of the parties is now or may become a resident of a different state. 

IN WITNESS WHEREOF, the Parties have caused this Amendment No. 1 to be signed by their duly authorized representatives as of the Amendment No. 1 Effective
Date. 
  

					
	FRED HUTCHINSON CANCER	 		 	JUNO THERAPEUTICS, INC.
	RESEARCH CENTER	 		 	
			
	 /s/ Nicole C. Robinson
	 		 	 /s/ Hans Bishop

	Signature	 		 	Signature
			
	 Nicole C. Robinson, Ph.D.
	 		 	 HANS BISHOP

	Printed Name	 		 	Printed Name
			
	 Vice President, Business Development Industry Relations
	 		 	 CHIEF EXECUTIVE OFFICER

	Title	 		 	Title
			
	 10/22/15
	 		 	 OCTOBER 22, 2015

	Date	 		 	Date

 [Signature Page to Amendment No. 1 to Amended and Restated Patent and 

Technology License Agreement] 

  

					
		 	Page 2 of 7	 	Juno Confidential

 EXHIBIT A 

PATENT RIGHTS 
 (as of
September 21, 2015) 
  

					
	SeedIP Ref (360056-)	  	 Application No.
  

Patent No./
 Publication
No.
	  	 Filing Date
  

Publication/ Issue

Date
  

(MM-DD-YYYY)

 407 Family 

[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 3 of 7	 	Juno Confidential

 [***] 

412 Family 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 4 of 7	 	Juno Confidential

 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 5 of 7	 	Juno Confidential

 425 Family 

[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 6 of 7	 	Juno Confidential

 [***] 

* FHCRC’s right, title and interest only. Co-Owned with Seattle Children’s Research Institute. 

427 Family 
 [***] 

433 Family 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	Page 7 of 7	 	Juno Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]